Immunological mechanisms elicited at the tumour site by lymphocyte activation gene‐3 (LAG‐3) versus IL‐12: sharing a common Th1 anti‐tumour immune pathway

@article{Carlo2005ImmunologicalME,
  title={Immunological mechanisms elicited at the tumour site by lymphocyte activation gene‐3 (LAG‐3) versus IL‐12: sharing a common Th1 anti‐tumour immune pathway},
  author={Emma Di Carlo and Paola Cappello and Carlo Sorrentino and Tommaso D'antuono and Antonella Pellicciotta and Mirella Giovarelli and Guido Forni and Piero Musiani and Frederic Triebel},
  journal={The Journal of Pathology},
  year={2005},
  volume={205}
}
The experimentally induced TS/A murine mammary carcinoma is poorly immunogenic and mainly infiltrated by antigen‐presenting cells (APCs), namely macrophages and immature dendritic cells (DCs). Human (h) and mouse (m) lymphocyte activation gene‐3 (LAG‐3 or CD233) is a physiological MHC class II ligand and powerful APC activator. A gene transfer approach has revealed its anti‐tumour activity in this model: hLAG‐3 was more effective than mLAG‐3. To obtain a clearer picture of the immunoregulatory… Expand

Paper Mentions

Interventional Clinical Trial
The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine. IMP321 is a… Expand
ConditionsPancreatic Neoplasms
InterventionBiological, Drug
A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy
TLDR
Investigation of HIV patients who were immunodeficient when they began antiretroviral therapy (ART) and had stable increases in CD4 T‐cell counts suggests that the elevation of IgE marks low cytokine responses, which is suggested to be an inverse correlation with IL‐5 released in culture. Expand
LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes
  • Y. He, Hui Yu, +9 authors F. Hirsch
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2017
TLDR
It is found that patients with both PD‐L1–negative tumor cells and LAG‐3–negative TILs have longer recurrence‐free survival than patients who are either PD‐ L1– or LAG–3–positive or both PD-L1- and Lag‐3‐positive. Expand
Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer
TLDR
The findings suggest that LAG3‐Ig‐P5‐immunoliposomes can be considered as a valuable candidate for developing a liposome‐based therapeutic cancer vaccine in treating HER2/ neu+ breast cancer patients. Expand
IL‐10 Contributes to the Suppressive Function of Tumour‐Associated Myeloid Cells and Enhances Myeloid Cell Accumulation in Tumours
TLDR
IL‐10 enhances the accumulation of myeloid cells in tumours, and TAMC‐derived IL‐10 suppresses the activation and expansion of tumour antigen–specific T cells. Expand
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
TLDR
Lymphocyte‐activation gene‐3 (LAG‐3) is another vital checkpoint that may have a synergistic interaction with PD‐1/PD‐L1, and the function in cancer, clinical trials with agents targeting LAG‐2 and the correlation of LAG-3 with other checkpoints are reviewed. Expand
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
TLDR
The activity of hLAG-3Ig in inducing tumor-associated, antigen-specific CD8+ T-cell responses in a human setting strongly support the conclusion that this recombinant protein is a potential candidate adjuvant for cancer vaccines. Expand
A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells
TLDR
IMP321 has many properties that confirm its potential to be a new class of immunopotentiator in cancer patients, and is effective at inducing in PBMCs an appropriate cytotoxic-type response in short-term ex vivo assays. Expand
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine.
TLDR
Overall, sCD30 and sCD223 levels seem to be promising candidate markers to assess the induction of Th-type responses in vaccine recipients, suggesting that the two markers are the expression of different and counter-regulated T-cell responses. Expand
IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study
TLDR
IMP321 as an adjuvant to HBsAg was well-tolerated and enhanced T cell response vaccine immunogenicity (i.e. induced both CD4 Th1 and CD8 Tc1 antigen-specific T cells) has allowed the development of IMP 321 as an immunopotentiator for therapeutic vaccines. Expand
Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors
TLDR
The data indicate that the promiscuously presented vaccine peptide HER- 2/neu(776-90) is amenable to Ii-Key-enhancing effects and supports the therapeutic potential of vaccinating patients with HER-2/neU+ tumors with such Ii -Key/HER-2-neu (776- 90) hybrid peptides. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 46 REFERENCES
Lymphocyte activation gene‐3 induces tumor regression and antitumor immune responses
TLDR
It is suggested that LAG‐3 could be used as a vaccine adjuvant for its ability to trigger APC via MHC class II molecules. Expand
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts.
TLDR
Support is provided for a role for TIL-expressed LAG-3 in the engagement of class II molecules on APCs, thereby contributing to APC activation and Th1/Tc1 commitment, without downregulating cytotoxicity. Expand
MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells.
TLDR
Evidence is provided that MHC class II signaling may affect DC migration to secondary lymphoid tissues, and the effect of a soluble LAG-3Ig molecule on theChemokine and chemokine receptor profile of human immature monocyte-derived DC is studied. Expand
Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II
Abstract The lymphocyte activation gene-3 (LAG-3), a major histocompatibility complex (MHC) class II ligand evolutionarily related to CD4, is expressed exclusively in activated T and NK lymphocytesExpand
CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins
TLDR
Results suggest that co‐engagement of the TcR with CD4 alters the CD4/MHC class II molecular interaction to become insensitive to LAG‐3Ig competition. Expand
Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)1
TLDR
The effect of LAG-3Ig on the maturation and activation of human monocyte-derived dendritic cells (DC) is reported, which increases the capacity of DC to stimulate the proliferation and IFN-γ response by allogeneic T cells. Expand
Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells.
TLDR
Similar to CD40L, LAG-3 may be involved in the proinflammatory activity of cytokine-activated bystander T cells and most importantly it may directly activate DC. Expand
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.
  • F. Triebel
  • Biology, Medicine
  • Trends in immunology
  • 2003
TLDR
Recent studies in mice have reconciled previous interpretations and clearly show that, as in human cells, LAG-3 negatively regulates T-cell function and homeostasis. Expand
A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens1
TLDR
Evidence is provided of a novel means of improving the immunogenicity of subunit vaccines by coadministration of a soluble fusion protein between murine LAG-3 and the Fc fraction of a murine IgG2a mAb as a vaccine adjuvant induced or increased CTL responses to the corresponding MHC class I-restricted peptide. Expand
Phenotypic analysis of the murine CD4‐related glycoprotein, CD223 (LAG‐3)
TLDR
It is shown that mRNA expression is restricted to the thymic medulla, splenic red pulp and sparse cells in the adult brain cortex, and a new monoclonal antibody (mAb) that recognizes an epitope in the D2 domain should greatly assist in the elucidation of CD223 function. Expand
...
1
2
3
4
5
...